Obiettivo The aim of SMILE is to support SiriusXT in moving a prototype of its soft x-ray microscope (SXT100) from prototype to commercial product through addressing ease-of-assembly, manufacturing scale-up, serviceability, customer pilots, regulatory pathways and business model requirements. The disruptive innovation delivered by SMILE is to open up the market for soft x-ray imaging from approx. 100 users today to an immediate target addressable market of over 3,000 disease research and drug discovery organisations by reducing the cost of the microscope assembly by a factor of over 200 (from over €500 million to €2.5 million) and miniaturizing its size, by a factor of 5,000 (from 15,000m2 area to approx. 3m2). Soft x-ray imaging is the only means available today of generating high resolution, high contrast, 3D images of the internal structure of whole biological cells in their near-natural state. Cell researchers currently spend approx. €500m annually on electron and optical microscopes in order to increase their understanding of subcellular structure and how this relates to disease progression and therapy, however neither of these technologies is capable of imaging the whole internal cell structure. The SXT100 gives disease research and drug discovery organisations daily access to a soft x-ray microscope in their own labs, rather than having to queue for often more than six months to get a few hours of access to one of only four synchrotron locations around the world where a suitable soft x-ray source and microscope exists today. The SXT100 will not only increase a researcher’s productivity 100-fold, in the number of biological cells they can image, but it also allows them to carry out a range of disease progression studies, not possible today because of the restricted access to these synchrotron microscopes.SMILE is predicted to have a significant impact in addressing the EU/global challenge in reducing the cost of healthcare delivery and developing cures for disease. Campo scientifico medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverynatural sciencesbiological sciencescell biologycell signalingnatural sciencesphysical sciencesopticsmicroscopyelectron microscopymedical and health sciencesclinical medicineoncologynatural sciencesphysical sciencestheoretical physicsparticle physicsphotons Programma(i) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Argomento(i) SMEInst-05-2016-2017 - Supporting innovative SMEs in the healthcare biotechnology sector Invito a presentare proposte H2020-SMEInst-2016-2017 Vedi altri progetti per questo bando Bando secondario H2020-SMEINST-2-2016-2017 Meccanismo di finanziamento SME-2 - SME instrument phase 2 Coordinatore SIRIUSXT LIMITED Contribution nette de l'UE € 3 000 935,00 Indirizzo 12 BREFFNI TERRACE, SANDYCOVE A96 XV67 Dublin Irlanda Mostra sulla mappa PMI L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione. Sì Regione Ireland Eastern and Midland Dublin Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Collegamenti Contatta l’organizzazione Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale € 3 000 935,00
